FOXP1

Overview

FOXP1 is a forkhead box transcription factor with roles in B-cell development and diverse cancers. In pancreatic cancer it has emerged as a subtype-specific alteration enriched in the other-MAPK-mutant genomic subgroup.

Alterations observed in the corpus

  • FOXP1 alterations are almost exclusive to the other-MAPK-mutant PDAC subtype; enriched compared to KRAS-mutant tumors (P = 5.3 × 10⁻⁵) and absent in MAPK-WT tumors in the MSK pdac_msk_2024 cohort (n = 2,336) PMID:39753968.
  • FOXP1 was recurrently altered in prostate cancer as identified by integrative genomic profiling of the MSKCC cohort PMID:20579941
  • Copy-number alteration observed in lung squamous cell carcinoma (178 tumors, TCGA) PMID:22960745
  • Early clonal deletion in the consensus prostate cancer progression path; one of the earliest detectable lesions identified by chromoplexy analysis PMID:23622249
  • Co-deleted in a 3p13 focal deletion identified by both aCGH and low-pass WGS in a prostate cancer FFPE biopsy proof-of-principle cohort; co-deleted with RYBP and SHQ1 PMID:25024180
  • Located in 3p21 focal heterozygous deletion region in MSK-PCa1 and MSK-PCa7 prostate cancer cell lines PMID:25201530
  • Recurrent 3p14 gain with breakpoints suggesting translocation in PCNSL PMID:25991819
  • Recurrent fusion partner in melanoma: MITF-FOXP1 fusion identified in BRAF-subtype cutaneous melanoma PMID:26091043
  • Part of a complex 3p13 deletion locus (with RYBP and SHQ1) in primary prostate cancer PMID:26544944
  • HD-defined TSG newly nominated as a breast-cancer Mut-driver; well-known driver in other cancer types suggesting potential for cross-cancer drug repurposing PMID:27161491
  • Mutation present in the untreated primary (TURBT) of patient WCM117 but absent from post-chemotherapy metastases (private to the eradicated clone); implicated in cellular cisplatin response alongside POLD2 PMID:27749842
  • FOXP1–ABL1 fusion detected in B-lymphoblastic leukemia (BLL) in the PIPseq pediatric cohort; classified as a TKI target and treated accordingly PMID:28007021.
  • Identified as a novel recurrently mutated gene (1–4% frequency) in microsatellite-stable metastatic colorectal cancer by MSK-IMPACT sequencing of 1,134 colorectal adenocarcinomas PMID:29316426
  • A cluster of events in the 5-prime end of FOXP1 was excluded by the Broad capture-BED (bitgt) filter in the MC3 pan-cancer mutation calling pipeline, illustrating how capture-kit masking discards biologically meaningful variants outside target regions. PMID:29596782

Cancer types (linked)

  • PAAD — alteration nearly exclusive to the other-MAPK-mutant PDAC subtype; co-listed with CREBBP as subtype-defining genes PMID:39753968.

Co-occurrence and mutual exclusivity

  • Co-enriched with CREBBP in the other-MAPK-mutant PDAC subtype; both are essentially absent in MAPK-WT tumors PMID:39753968.

Therapeutic relevance

  • Not reported in the corpus.

Open questions

  • Functional role of FOXP1 in shaping the other-MAPK-mutant PDAC phenotype is not established PMID:39753968.

Sources

This page was processed by crosslinker on 2026-05-14. - PMID:26544944

This page was processed by crosslinker on 2026-05-14. - PMID:27161491

This page was processed by wiki-cli on 2026-05-14. - PMID:27749842

This page was processed by entity-page-writer on 2026-05-15. - PMID:28007021

This page was processed by wiki-cli on 2026-05-14. - PMID:29316426

This page was processed by wiki-cli on 2026-05-15. - PMID:29596782

This page was processed by wiki-cli on 2026-05-15.